Rapport Therapeutics, Inc. RAPP Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$19.86M+41.2% | -$33.76M-25.4% | -$26.93M-0.7% | -$26.73M-11.1% | -$24.06M-20.4% | ||
| $227K-14.3% | $265K+3.5% | $256K+1.6% | $252K+3.3% | $244K-6.2% | ||
| $6.96M+22.4% | $5.69M+20.2% | $4.74M+7.9% | $4.39M+8.6% | $4.04M+25.9% | ||
| $58K— | —— | —— | —— | $0— | ||
| $2.31M+95.7% | $1.18M— | $0-100% | $1.03M+457% | $185K— | ||
| -$3.49M-195% | $3.69M+117% | $1.7M+274% | $453K+36.9% | $331K-61.0% | ||
| -$814K-182% | $987K— | —— | $4.32M+424% | $825K+6,775% | ||
| $582K+1.9% | $571K+0.7% | $567K+17.4% | $483K+17.5% | $411K+149% | ||
| -$13.06M+47.1% | -$24.7M-41.4% | -$17.47M+30.3% | -$25.07M-23.9% | -$20.24M-40.1% | ||
| $86K-49.1% | $169K+26.1% | $134K+509% | $22K-92.4% | $291K+28.8% | ||
| $30.37M-84.6% | $197.07M+93.9% | $101.62M+690% | $12.86M-70.3% | $43.24M-48.9% | ||
| $58.32M+155% | $22.92M-49.1% | $44.98M+26.8% | $35.48M-45.0% | $64.56M-44.7% | ||
| $37.94M+122% | -$174.32M-207% | -$56.78M-351% | $22.6M+7.4% | $21.03M— | ||
| $809K+14.6% | $706K+11.0% | $636K— | $0-100% | $6K+243% | ||
| $273K— | —— | —— | $63K— | $0— | ||
| $531K+70.7% | $311K-99.9% | $270.53M+429,517% | -$63K-1,360% | $5K-28.6% | ||
| $25.41M+113% | -$198.71M-201% | $196.29M+7,837% | -$2.54M-418% | $799K— | ||
| $364K-66.0% | $1.07M— | —— | $92K-78.9% | $436K— | ||
| -$3.49M-195% | $3.69M+117% | $1.7M+274% | $453K+36.9% | $331K-61.0% | ||
| $681K+75.1% | $389K— | $0-100% | $38K-47.9% | $73K-58.3% | ||
| -$346K— | —— | $362K-27.2% | $497K+875% | $51K+259% | ||
| -$814K-182% | $987K— | —— | $4.32M+424% | $825K+6,775% | ||
| $582K+1.9% | $571K+0.7% | $567K+17.4% | $483K+17.5% | $411K+149% | ||
| $58.32M+155% | $22.92M-49.1% | $44.98M+26.8% | $35.48M-45.0% | $64.56M-44.7% | ||
| $10.08M— | —— | —— | —— | $0— | ||
| $5K— | —— | —— | —— | $1K— | ||
| $49K— | —— | —— | —— | $0-100% | ||
| $180K— | —— | —— | —— | $0— | ||
| $0— | —— | —— | $4.06M-36.9% | $6.44M— | ||
| -$13.15M+47.1% | -$24.87M-41.3% | -$17.6M+29.9% | -$25.09M-22.2% | -$20.53M-39.9% | ||
| -$13.15M+47.1% | -$24.87M-41.3% | -$17.6M+29.9% | -$25.09M-22.2% | -$20.53M-39.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Rapport Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Rapport Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.